Small molecule targeted drugs for the treatment of CRC recommended by the NCCN guidelines mainly includes anti-EGFR such as cetuximab and anti-VEGF such as bevacizumab and panitumumab [49]. The gene discussed is EGFR; the disease is colorectal carcinoma.